ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Challenges Use Of Avastin In UK To Treat Eye Disease

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Swiss drug maker Novartis (NVS) is challenging the use of a unlicensed cheaper medicine to treat an eye disease in the U.K. as an alternative to its drug Lucentis. "It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available," Novartis said in a statement. "It undermines the regulatory process that was introduced to safeguard patients." Novartis also said there is "emerging evidence" of potential safety concerns on the use of Avastin, or bevacizumab, to treat a neovascular form of age related macular degeneration, known as wet AMD. The BBC Tuesday said Novartis was seeking a judicial review of the policy to pay for Avastin on the publicly funded National Health Service, after the NHS in four areas in the south of England agreed last year that Avastin could be prescribed for the condition. Novartis declined to comment on whether it was seeking the review. Lucentis, Novartis' best-selling eye drug which generated $2.05 billion in sales in 2011, is recommended for use by the NHS to treat wet age-related macular degeneration. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
06/06/201605:11:00Mereo BioPharma to Trade on AIM -- Update
05/23/201616:40:00Samsung Targets U.S. Drug Market With Remicade Knockoff
05/20/201615:20:00Colombia Threatens to Override Novartis's Patent on Gleevec
05/20/201615:18:00Colombia Threatens to Override Novartis's Patent on Gleevec
05/18/201603:03:00Novartis Says Drug-Unit Chief To Leave Firm -- WSJ
05/17/201618:43:00ADRs End Lower; NQ Mobile Rises
05/17/201615:11:00Novartis to Split Pharmaceuticals Division into Two -- Update
05/17/201614:10:00Novartis to Split Drug Division
05/17/201613:27:00Novartis to Split Pharmaceuticals Division Into Two
05/05/201620:58:00Upsized IPO of Biotech Company Intellia Prices at Top of Range
05/03/201608:30:00Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
05/03/201608:19:00Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
04/29/201604:50:00AstraZeneca's Investment Eats Into Profit
04/28/201616:40:00Amgen Profit Rises 17%, Guidance Raised
04/27/201608:20:00GlaxoSmithKline Sees First-Quarter Profit Fall
04/26/201608:10:00Eli Lilly Revenue Boosted By New Drug Sales
04/22/201603:03:00Novartis Feels the Effect Of Drop in Gleevec Sales -- WSJ
04/21/201608:29:00Novartis Earnings Fall on Slide in Cancer-Drug Sales -- 2nd Update
04/21/201603:50:00Novartis Earnings Fall on Slide in Cancer-Drug Sales --Update
04/21/201602:10:00Novartis Earnings Fall on Slide in Cancer-Drug Sales

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad